Primary Hyperoxaluria Type 1Symptoms, Doctors, Treatments, Advances & More
Primary Hyperoxaluria Type 1 Overview
Learn About Primary Hyperoxaluria Type 1
- Primary hyperoxaluria type 1
- Alanine-glyoxylate aminotransferase deficiency
- Glycolic aciduria
- HP1
- Hepatic AGT deficiency
- Oxalosis 1
- Peroxisomal alanine glyoxylate aminotransferase deficiency
- Serine pyruvate aminotransferase deficiency
Pierre Cochat practices practicing medicine in Bron, France. Mr. Cochat is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.
Yaacov Frishberg practices practicing medicine in Jerusalem, Israel. Mr. Frishberg is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria Type 1, Primary Hyperoxaluria, Nephrocalcinosis, Calcinosis, and Kidney Transplant.
Mayo Clinic-Rochester
John Lieske is a Nephrologist practicing medicine in Rochester, Minnesota. Dr. Lieske is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Kidney Stones, Nephrocalcinosis, Primary Hyperoxaluria, Kidney Transplant, and Nephrectomy. Dr. Lieske is currently accepting new patients.
Summary: This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infu...
Summary: This is a single-arm, open-label, single-dose dose-escalation study. It aims to evaluate the safety and tolerability of YOLT-203 in Chinese patients with Primary Hyperoxaluria Type 1 (PH1), and to preliminarily assess the effect of a single administration of YOLT-203 on 24-hour urinary oxalate excretion. The clinical trial will first evaluate the safety and tolerability in adult patients. After th...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
